Introduction
In 1992 Chang and co-workers reported a favourable effect of octreotide treatment on the signs and symptoms of Graves' ophthalmopathy. 1 They hypothesized that octreotide, a potent long-acting somatostatin analogue, may inhibit local synthesis of insulin-like growth factor-1 (IGF-1) by orbital fibroblasts, thereby reducing glycosaminoglycan production. The hypothesis is theoretically supported by the presence of immunoreactivity to IGF-1 in extraocular muscles and fat cells 2 , and
by the suppression of IGF-1 in serum by octreotide. Krenning and co-workers used radiolabeled octreotide in patients with Graves' disease. 3 By radiolabelling octreotide, tissues which express somatostatin receptors can be visualized.
Applying [ m In-DTPA-D-Phel] octreotide scintigraphy specific uptake of the radiolabel was observed in the thyroid and orbit of some but not all patients with
Graves' disease. In this review we will discuss the determinants of thyroidal and orbital uptake of radiolabeled octreotide and the clinical relevance of octreotide scintigraphy in patients with Graves' disease. Table 1 . If thyroidal uptake of radiolabeled octreotide was set at 100% at 5h postinjection, the uptake at 24h postinjection decreased to 68±19% in patients with Graves' disease, similar to that in controls (58±12%). This decrease was significantly less than the decrease in blood pool radioactivity (from 100% to 15±4%), indicating specific uptake in the thyroid gland. The first orbital octreotide scans in Graves' disease have been reported by Postema et al. 3 If peak activity in the orbit 5h after injection of radiolabeled octreotide is set at 100%, a decrease to 40±4% is found at 24h, significantly different from the decrease in blood pool radioactivity (from 100% at 5h to 15±4% at 24 h). The cause of specific orbital uptake is unknown. An attractive hypothesis is that orbital uptake in Graves' disease is caused by the expression of somatostatin receptors on activated T-lymphocytes, thus visualizing the lymphocytic infiltrate in retrobulbar tissues. Alternative explanations cannot, however, be excluded like binding to receptors on other cell types (e.g. eye muscle cells, fibroblasts, endothelial cells)
or local blood pooling due to venous stasis by the auto-immune orbital inflammation. Systemic hypercirculation seems only partly responsible, as evident from the rather low orbital uptake in Graves' hyperthyroid patients without clinical signs of ophthalmopathy. 3 Some studies report a relationship between orbital octreotide accumulation and the severity of Graves' ophthalmopathy, with higher uptake values in more severe eye disease 3, 8 ; severity in these studies is indicated by a higher class or grade in the NO ; the uptake in the inactive group is close to that in control subjects in whom no specific uptake is observed. Orbital octreotide scintigraphy could thus be applied in clinical practice to select patients with Graves' ophthalmopathy who will benefit from immunosuppression.
To this end one must know the predictive value of orbital octreotide uptake for the outcome of immunosuppressive treatment; such data are, however, scarce, as are data about the precision and accuracy of the technique. There are wide differences between various studies in the administered dose of [ m In-DTPA-d-Phe] octreotide, the time interval after injection for determining the orbital uptake, the selection of orbital slices for quantification of the orbital uptake, and the method of correction for background radioactivity ( Table 2 ). The earlier studies used rather large doses of radiolabeled octreotide (as usual in the visualization of neuroendocrine tumors), and preferred to determine orbital uptake 24h post injection. In disagreement, Krassas and Dumas 13 state that a low dose might cause problems in count statistics, and that 2h after injection 12% of the dose is still in the blood pool causing high background uptake; furthermore they indicate that the radiation burden received from a high dose of 222 MBq is 16 mSy, in the same order as that from chest computed tomography or angiography. It must be admitted that the difference in orbital octreotide uptake between patients with active and inactive eye disease is smaller at 24h than at 4h after injection of a low dose (own unpublished observations). 8 The inference is that for discrimination purposes a 4h time interval is preferred when a low dose is chosen. On the other hand, any remaining orbital radioactivity at 24h after administering a high dose might represent to a greater degree specific tissue binding, possibly enhancing the predictive value of the octreoscan. Future studies should take into account this specific point. Another technical bias is the selection of orbital regions of interest, which may result in considerable intra-and inter-observer variation. SPECT images are obviously required, and measuring uptake in a number of orbital slices from SPECT images is of great advantage in the quantification of results.
Correction for background activity has originally been performed by using the left temporal skull area. 3, 12 Uptake in this area is considerable, ascribed to radioactivity in the intracranial venous sinuses. We have recently obtained evidence that at least part of this radioactivity is due to uptake in the parotid gland; consequently we now prefer background measurements in the occipital skull area. Brain itself is used to measure background 8, 910 , but seems less suitable to correct for blood pool radioactivity.
Patients with very active eye disease are bound to respond favourably to immunosuppression; the activity of the eye disease in such cases is clinically evident at first glance, and would not require further assessment with octreotide scintigraphy. In many patients with moderately severe ophthalmopathy, however, it is not at all clear whether or not the eye disease is still in the active stage and whether or not the patient will benefit from immunosuppression. Under these circumstances orbital octreotide scintigraphy might be used as a predictor for outcome of immunosuppression. This will require calculation of the orbital to skull uptake ratio using quantitative measurements in well-defined regions of interest of SPECT slices. The only study in this respect is that of Krassas and coworkers 12 who observed the following orbital to skull uptake ratio's 24h after 244 
